Barinthus Biotherapeutics plc (FRA:2AB)

Barinthus Biotherapeutics Statistics

Total Valuation

FRA:2AB has a market cap or net worth of EUR 23.89 million. The enterprise value is -23.24 million.

Market Cap	23.89M
Enterprise Value	-23.24M

Important Dates

The next estimated earnings date is Thursday, July 30, 2026.

Earnings Date	Jul 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.40%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	11.74%
Owned by Institutions (%)	31.12%
Float	27.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	0.41
P/TBV Ratio	0.52
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.51
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.17.

Current Ratio	6.05
Quick Ratio	5.59
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-856.79

Financial Efficiency

Return on equity (ROE) is -57.49% and return on invested capital (ROIC) is -26.64%.

Return on Equity (ROE)	-57.49%
Return on Assets (ROA)	-23.33%
Return on Invested Capital (ROIC)	-26.64%
Return on Capital Employed (ROCE)	-54.52%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-3.24M
Employee Count	14
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-146,574
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.00% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.00%
50-Day Moving Average	0.50
200-Day Moving Average	0.73
Relative Strength Index (RSI)	57.96
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-115,351
Operating Income	-37.90M
Pretax Income	-45.54M
Net Income	-45.37M
EBITDA	-35.88M
EBIT	-37.90M
Earnings Per Share (EPS)	-1.12

Balance Sheet

The company has 57.12 million in cash and 9.55 million in debt, with a net cash position of 47.57 million.

Cash & Cash Equivalents	57.12M
Total Debt	9.55M
Net Cash	47.57M
Net Cash Per Share	n/a
Equity (Book Value)	57.66M
Book Value Per Share	1.41
Working Capital	52.61M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	1.99M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:2AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.40%
Shareholder Yield	-2.40%
Earnings Yield	-189.92%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a